GlassScriptPhysician profile
Cecilia Freeman
NPI 1508435124
$4,586.33
in general payments reported to CMS, 2019-2025
22 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $1,024 · 2023: $586 · 2024: $2,080 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Travel and Lodging: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.02 |
| Travel and Lodging | $1,143.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,292.84 | 2024-2025 | Inspire |
| Genzyme Corporation | $692.27 | 2022-2025 | |
| Csl Behring | $474.53 | 2022-2024 | Haegarda, Hizentra |
| Regeneron Healthcare Solutions, INC. | $458.35 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $365.78 | 2022-2023 | Nucala |
| Optinose US, INC. | $332.80 | 2022-2025 | |
| Harmony Biosciences LLC | $148.04 | 2024-2025 | |
| Neurent Medical Limited | $147.67 | 2022-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Phathom Pharmaceuticals, INC. | $144.31 | 2025 | Voquezna |
| Pharming Healthcare, INC. | $128.52 | 2022-2023 | Joenja |
| Integra Lifesciences Corporation | $122.66 | 2024 | Acclarent Aera |
| Boston Scientific Corporation | $41.15 | 2021 | |
| Philips North America LLC | $39.23 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Stryker Corporation | $38.11 | 2022 | |
| Convatec INC. | $32.96 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $22.71 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $22.40 | 2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $21.67 | 2024 | Xembify |
| Aimmune Therapeutics, INC. | $20.36 | 2021 | |
| Axsome Therapeutics, INC. | $14.29 | 2025 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.